A5082987648- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Diverticular Disease and Complications
- Autoimmune and Inflammatory Disorders
- Celiac Disease Research and Management
- Immunodeficiency and Autoimmune Disorders
- Liver Diseases and Immunity
- Helicobacter pylori-related gastroenterology studies
- Health Systems, Economic Evaluations, Quality of Life
- Diagnosis and treatment of tuberculosis
- Adolescent and Pediatric Healthcare
- Gastrointestinal disorders and treatments
- Biosimilars and Bioanalytical Methods
- Gastric Cancer Management and Outcomes
- Pregnancy and Medication Impact
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Treatments and Studies
- COVID-19 Clinical Research Studies
- COVID-19 and healthcare impacts
- Chronic Lymphocytic Leukemia Research
- Hidradenitis Suppurativa and Treatments
- Pharmaceutical studies and practices
- Anorectal Disease Treatments and Outcomes
- Autoimmune and Inflammatory Disorders Research
Case Western Reserve University
2023-2025
Cleveland Clinic
2018-2025
Cleveland Clinic Lerner College of Medicine
2019-2025
University Hospitals of Cleveland
2023
BioFire Diagnostics (United States)
2023
Janssen (Switzerland)
2023
AbbVie (United States)
2023
Takeda (Japan)
2023
Shionogi (United States)
2023
Bristol-Myers Squibb (Switzerland)
2023
Crohn's disease is an idiopathic inflammatory disorder of unknown etiology with genetic, immunologic, and environmental influences. The incidence has steadily increased over the past several decades. diagnosis treatment patients evolved since last practice guideline was published. These guidelines represent official recommendations American College Gastroenterology were developed under auspices Practice Parameters Committee for management adult disease. are established clinical intent...
Background & AimsMost patients with Crohn's disease (CD) eventually require an intestinal resection. However, CD frequently recurs after We performed a randomized trial to compare the ability of infliximab vs placebo prevent recurrence.MethodsWe evaluated efficacy in preventing postoperative recurrence 297 at 104 sites worldwide from November 2010 through May 2012. All study had undergone ileocolonic resection within 45 days before randomization. Patients were randomly assigned (1:1) groups...
Intestinal epithelial cell (IEC) apoptosis contributes to the development of ulcerative colitis (UC), an inflammatory bowel disease (IBD) that affects colon and rectum. Therapies target cytokine TNF have been found inhibit IEC in patients with IBD, although mechanism remains unclear. We therefore investigated role p53-upregulated modulator (PUMA), a p53 proapoptotic BH3-only protein, apoptosis, using patient samples mouse models UC. In UC samples, PUMA expression was elevated tissues...
OBJECTIVES: In classifying Crohn's disease (CD) location, proximal (L4) includes esophagogastroduodenal (EGD) and jejunal disease. Our aim was to determine the influence of on outcomes behavior need for surgery if there significant clinical heterogeneity between EGD METHODS: We performed a cross-sectional query NIDDK (National Institute Diabetes Digestive Kidney Disease) Inflammatory Bowel Disease Genetics Consortium (IBDGC) database patients with confirmed diagnosis CD phenotyped per IBDGC...
Obesity has been linked with a proinflammatory state and the development of inflammatory diseases. Data on clinical course treatment obese patients bowel disease (IBD) are limited. We used an institutional IBD registry to investigate impact obesity severity treatment.This was retrospective analysis prospectively collected data for 3 years (2009-2011). Patients were categorized by body mass index (BMI). IBD-related quality life, biochemical markers inflammation, comorbidities, health care...
Crohn's disease clinical trials utilize the Disease Activity Index (CDAI) to measure primary endpoint assessments of recurrence and remission. We evaluated extent agreement between recurrence/remission as defined by CDAI endoscopic 1 year after intestinal resection for (CD).Twenty-four CD patients who had been randomly assigned a postoperative trial clinical, endoscopic, histological assessment recurrence. The was CD. Secondary endpoints were surrogate markers activity, i.e., sedimentation...
Abstract Crohn Disease (CD) is a complex genetic disorder for which more than 140 genes have been identified using genome wide association studies (GWAS). However, the architecture of trait remains largely unknown. The recent development machine learning (ML) approaches incited us to apply them classify healthy and diseased people according their genomic information. Immunochip dataset containing 18,227 CD patients 34,050 controls enrolled genotyped by international Inflammatory Bowel...
We evaluated the real-world effectiveness and safety of ustekinumab (UST) in patients with Crohn's disease (CD).This study used a retrospective, multicenter, multinational consortium UST-treated CD patients. Data included patient demographics, phenotype, activity, treatment history, concomitant medications. Cumulative rates clinical, steroid-free, endoscopic, radiographic remissions were assessed using time-to-event analysis, clinical predictors by multivariate Cox proportional hazard...
Abstract Backgrounds and Aims This interim analysis from the True North open-label extension [OLE] study examines efficacy safety of approximately 3 years continuous ozanimod treatment in patients with moderately to severely active ulcerative colitis. Methods Clinical responders after 52 weeks during phase study, who continued OLE, were evaluated. Efficacy, including endoscopic histological endpoints, was assessed OLE for 2 additional through Week 94, using observed case [OC] nonresponder...
Abstract Background The SEQUENCE study compared the efficacy and safety of risankizumab (RZB) ustekinumab (UST) in patients (pts) with moderate-to-severe Crohn's disease (CD) who previously failed ≥1 anti-tumour necrosis factor (TNF)a therapies. second primary endpoint SEQUENCE, week (wk) 48 endoscopic remission, demonstrated superiority RZB versus (vs) UST.1 Here, additional clinical/endoscopic composite outcomes are reported. Methods (NCT04524611) was an open-label, multicenter,...
Introduction: Patients with ulcerative colitis (UC) and prior biologic failure may have reduced or delayed efficacy subsequent advanced therapies. This analysis evaluated the safety of ozanimod during True North (TN) study its open-label extension (OLE) in biologic-exposed patients UC. Methods: TN was a randomized, placebo-controlled 52-week trial (10-week induction, 42-week maintenance period). Eligible could enter OLE. Clinical outcomes were assessed at Week (W) 10 W52 OLE W46 W94....
Semaglutide, a glucagon-like peptide-1 receptor agonist, has shown sustained and clinically significant weight loss in the general population. There are limited data on outcomes of its use patients with inflammatory bowel disease (IBD).